Shareholders of Hao Tian International Construction Investment Group (HKG:1341) and its controlling shareholder Aceso Life Science (HKG:0474) will meet March 18 to vote on a proposed share placement by the former, a Tuesday filing with the Hong Kong bourse said.
Hao Tian International Construction, in October, had agreed to place 1,524,224,000 shares to at least six placees to raise around HK$600 million.
Assuming full completion, Aceso Life Science's stake in Hao Tian International Construction will be diluted from roughly 29.05% to 24.2%.
The dilution will constitute a deemed disposal since Hao Tian International Construction Investment will no longer be considered a unit of Aceso Life Science and the financial results of the former will no longer be consolidated in the financial statements of the latter.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。